Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
AMRI Buys Spanish API Maker Gadea
by Michael McCoy
July 20, 2015
| A version of this story appeared in
Volume 93, Issue 29
The contract research and manufacturing firm Albany Molecular Research Inc. has acquired Gadea Pharmaceutical, a Spanish maker of active pharmaceutical ingredients (APIs) and finished drugs, for $174 million. Gadea, which had sales last year of $83 million, produces complex APIs including steroids and hormones in its Crystal Pharma division. Two other divisions make finished-dose drugs. AMRI says the deal enhances its complex API offerings and its global reach. AMRI’s last move into Europe was the 2010 purchase of an API plant in Wales, but the firm is now in the process of closing it.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter